CC618

CAS No. 1680204-90-3

CC618( —— )

Catalog No. M28891 CAS No. 1680204-90-3

CC618 is a selective PPARβ/δ antagonist with an IC50 of 10.0 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 314 In Stock
5MG 249 In Stock
10MG 369 In Stock
25MG 562 In Stock
50MG 770 In Stock
100MG 1032 In Stock
200MG 1376 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CC618
  • Note
    Research use only, not for human use.
  • Brief Description
    CC618 is a selective PPARβ/δ antagonist with an IC50 of 10.0 μM.
  • Description
    CC618 is a selective PPARβ/δ antagonist with an IC50 of 10.0 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    Hedgehog
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1680204-90-3
  • Formula Weight
    523.47
  • Molecular Formula
    C20H15F6N3O3S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cc1c(C(NCCS(c2ncc(C(F)(F)F)cc2)(=O)=O)=O)sc(-c2ccc(C(F)(F)F)cc2)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Williams JA, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions.Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21. Epub 2003 Apr 4.
molnova catalog
related products
  • 1-Deoxynojirimycin

    1-Deoxynojirimycin is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.

  • Cevoglitazar

    Cevoglitazar (LBM-642) is a PPARɑ agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys.

  • BMS-687453

    A potent and selective PPARα agonist with EC50 of 10 nM for human PPARα and 410-fold selectivity over human PPARγ in PPAR-GAL4 transactivation assays.